Lactobacilli and Bifidobacterium as anti-atherosclerotic agents

被引:2
|
作者
Abdi, Milad [1 ]
Ghaleh, Hadi Esmaeili Gouvarchin [2 ]
Ranjbar, Reza [3 ]
机构
[1] Kerman Univ Med Sci, Res Ctr Trop & Infect Dis, Kerman, Iran
[2] Baqiyatallah Univ Med Sci, Appl Virol Res Ctr, Tehran, Iran
[3] Baqiyatallah Univ Med Sci, Syst Biol & Poisonings Inst, Mol Biol Res Ctr, Tehran, Iran
关键词
Atherosclerosis; Bifidobacterium; Hypercholesterolemia; Inflammation; Lactobacilli; Oxidative stress; TMAO; TRIMETHYLAMINE N-OXIDE; BILE-SALT HYDROLASE; CHAIN FATTY-ACIDS; LIVER-X-RECEPTOR; CHOLESTEROL-LOWERING EFFICACY; PICK C1-LIKE 1; LIPID PROFILE; OXIDATIVE STRESS; SERUM-CHOLESTEROL; RISK-FACTORS;
D O I
10.22038/IJBMS.2022.63860.14073
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Atherosclerosis is the thickening or hardening of the arteries which is caused by a buildup of atheromatous plaque in the inner lining of an artery. Hypercholesterolemia, inflammation, oxidative stress, and trimethylamine N-oxide (TMAO) are important risk factors for atherosclerosis. Therefore, this study aimed to review the anti-atherosclerotic effects of Lactobacilli and Bifidobacterium via improving lipid profile and reducing the effects of oxidative stress, inflammation, and TMAO. To prepare the present review, several databases such as Scopus, PubMed, and Google Scholar were searched, and relevant articles from 1990 until 2022 were selected and reviewed. The present review showed that Lactobacilli and Bifidobacterium reduce the risk of atherosclerosis in both in vitro and in vivo studies by breaking down or altering cholesterol metabolism with the help of their by-products and by reducing inflammation and oxidative stress and TMAO. Consumption of Lactobacilli and Bifidobacterium can be useful in prevention of atherosclerosis.
引用
收藏
页码:934 / 946
页数:13
相关论文
共 50 条
  • [31] ANTI-ATHEROSCLEROTIC EFFECTS OF SQUALENE SYNTHASE INHIBITORS
    Tavridou, A.
    Manolopoulos, V.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [32] Anti-atherosclerotic effect of incretin receptor agonists
    Wang, Xin
    Yang, Xin
    Qi, Xiaoyan
    Fan, Gang
    Zhou, Lingzhi
    Peng, Zhengliang
    Yang, Jing
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [33] Experimental study of the anti-atherosclerotic effect of demethylzeylasteral
    Huang, Ying
    Wang, Shaofeng
    Zhang, Chunya
    Xu, Zhiqing
    Shen, Jinghua
    Du, Xiaogang
    Zhang, Huanhua
    Zhang, Kangjian
    Zhang, Daifu
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 13 (06) : 2787 - 2792
  • [34] Potentiality of ACAT inhibitors as anti-atherosclerotic drugs
    Shirahase, Hiroaki
    Kunishiro, Kazuyoshi
    Miike, Tomohiro
    Kanda, Mamoru
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2007, 127 : 44 - 47
  • [35] Novel Targets and Biomarkers for Anti-atherosclerotic Therapy
    Bobryshev, Yuri V.
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (33) : 5837 - 5839
  • [36] The role of cepharanthine as an anti-atherosclerotic agent in rats
    Iqbal, Adnan
    Najam, Rahila
    Khan, Saira Saeed
    Imran, Sumera
    Osama, Muhammad
    Tahir, Anosh
    Imran, Muhammad
    Jawed, Bilal
    Ahmed, Zeeshan
    Ishaqui, Azfar Athar
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 36 (04) : 1073 - 1077
  • [37] Endothelial function for the evaluation of anti-atherosclerotic drugs
    Kenji Okumura
    Xian Wu Cheng
    Hypertension Research, 2010, 33 : 780 - 781
  • [38] Anti-atherosclerotic activity of catechins depends on their stereoisomerism
    Mika, Magdalena
    Kostogrys, Renata B.
    Franczyk-Zarow, Magdalena
    Wikiera, Agnieszka
    Maslak, Edyta
    ATHEROSCLEROSIS, 2015, 240 (01) : 125 - 130
  • [39] Mechanisms of Atherogenesis and Development of Anti-Atherosclerotic Therapy
    Orekhov, Alexander N.
    CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (09) : 1103 - 1106
  • [40] NEW STRATEGIES IN THE DEVELOPMENT OF ANTI-ATHEROSCLEROTIC DRUGS
    SIRTORI, CR
    TREMOLI, E
    PAOLETTI, R
    ARTERY, 1980, 8 (06) : 507 - 518